Projects per year
Personal profile
Personal profile
After obtaining his MD and PhD, Dr. Zu attended the University of Connecticut Health Center as a postdoctoral fellow and later remained there as an assistant professor. He then spent four years in pathology residency training at New York University, followed by a two-year hematopathology fellowship at the National Cancer Institute of the National Institutes of Health. Dr. Zu joined the Department of Pathology and Genomic Medicine at Houston Methodist Hospital in 2004, where he currently serves as the Medical Director of the Hematopathology Section. He is also a Professor of Pathology and Laboratory Medicine at the Weill Cornell Medical College of Cornell University. In addition to his clinical responsibilities, Dr. Zu is also the Director of the Cancer Pathology research laboratory at the Houston Methodist Research Institute. These combined positions enable him to address clinically driven questions. As a physician-scientist, Dr. Zu has pioneered the translation of oligonucleotide aptamers and nanotechnology into clinical applications, and his research is currently funded by multiple NIH and CPRIT grants.
Research interests
Dr. Zu's clinical interests include diagnosis of hematopoietic and lymphoid disorders. His research centers on the development of novel diagnostics and treatments for these disorders. His laboratory was the first to use aptamer probes to enhance the diagnostic capabilities of multi-color flow cytometry and immunohistochemical staining for rapid detection of circulating tumor cells in whole-blood samples. By combining nanotechnology with aptamer technology, Dr. Zu's laboratory is developing new multi-functional nanomedicines for tumor-specific imaging and targeted therapy of several cancer types, including lymphomas, multiple myeloma, pancreatic cancer, breast cancer, prostate cancer, ovarian cancer, and hepatocellular (liver) carcinoma. Other areas of interest in his laboratory include the role of cancer stem cells in the development of multiple myeloma and the molecular mechanisms underlying myelodysplastic syndrome.
Education/Academic qualification
Hematopathology, Clinical Fellowship, National Cancer Institute (NCI)
Jul 1 2002 → Jun 30 2004
Award Date: Jun 30 2004
Pathology, Residency, New York University Medical Center
Jul 1 1998 → Jun 30 2002
Award Date: Jun 30 2002
Postdoctoral Fellowship, University of Connecticut Health Center
Jul 1 1992 → Jun 30 1998
Award Date: Jun 30 1998
Postdoctoral Fellowship, Tsukuba Life Science Research Center, RIKEN
Feb 1 1990 → Jun 30 1992
Award Date: Jun 30 1992
PhD, Kyoto University Graduate School of Medicine
Oct 1985 → Jan 1 1990
Award Date: Jan 1 1990
MD, Jilin Medical College
Apr 1 1978 → Dec 1 1982
Award Date: Dec 1 1982
Research Area Keywords
- Precision Medicine
- Cancer
- Nanomedicine
- Infectious Disease & Pathology
Free-text keywords
- Aptamer technology
Fingerprint
- 1 Similar Profiles
Network
-
Self-assembled multifunctional aptamer-complex biomaterial for precision medicine
1/15/18 → 12/31/22
Project: Federal Funding Agencies
-
-
Development of a Point-of-Care Volumetric Bar-Chart Chip for Drug Quantitation
Qin, L. & Zu, Y.
6/15/18 → 3/31/21
Project: Federal Funding Agencies
-
High Throughput Single-Cell Phenotype Isolation by Protrusion Analysis Chip (PAC)
Qin, L., Zu, Y. & Zhang, K.
8/15/15 → 7/31/18
Project: Federal Funding Agencies
Research output
-
Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer
Wan, Q., Zeng, Z., Qi, J., Chen, Z., Liu, X. & Zu, Y., 2022, (Accepted/In press) In: Molecular Therapy.Research output: Contribution to journal › Article › peer-review
-
Aptamer Targets Triple-Negative Breast Cancer through Specific Binding to Surface CD49c
Wan, Q., Zeng, Z., Qi, J., Zhao, Y., Liu, X., Chen, Z., Zhou, H. & Zu, Y., Mar 1 2022, In: Cancers. 14, 6, 1570.Research output: Contribution to journal › Article › peer-review
Open Access -
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms
Albitar, M., Zhang, H., Goy, A., Xu-Monette, Z. Y., Bhagat, G., Visco, C., Tzankov, A., Fang, X., Zhu, F., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F. B., Huh, J., Ponzoni, M., Ferreri, A. J. M., Møller, M. B., Parsons, B. M. & 6 others, , Feb 2022, In: Blood Cancer Journal. 12, 2, 25.Research output: Contribution to journal › Article › peer-review
Open Access -
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma
Xu-Monette, Z. Y., Wei, L., Fang, X., Au, Q., Nunns, H., Nagy, M., Tzankov, A., Zhu, F., Visco, C., Bhagat, G., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F. B., Sun, X., Han, X., Go, H., Ponzoni, M. & 11 others, , Mar 1 2022, In: Clinical Cancer Research. 28, 5, p. 972-983 12 p.Research output: Contribution to journal › Article › peer-review
-
Next-Generation Sequencing Revealed a Distinct Immunoglobulin Repertoire with Specific Mutation Hotspots in Acute Myeloid Leukemia
Xia, M., Wu, L., Sun, X., Han, X., Yan, H., Huang, J., Zhang, Y., Hu, Z., Zu, Y., Yin, C. C. & Qiu, X., Feb 2022, In: Biology. 11, 2, 161.Research output: Contribution to journal › Article › peer-review
Open Access